Achillion Pharmaceuticals

INVESTORS

Press Releases

 
Press Releases
  Date Title View
Feb 8, 2007
FOSTER CITY, Calif. and NEW HAVEN, Conn., Feb 08, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Gilead Sciences (Nasdaq: GILD) and Achillion Pharmaceuticals (Nasdaq: ACHN) today announced their decision to discontinue the development of GS 9132, also known as ACH-806, for the treatment of hepatitis C viral (HCV) infection, based upon preli...
PDF
Feb 5, 2007
NEW HAVEN, CT, February 5, 2007 — Achillion Pharmaceuticals, Inc. today announced that John C. Pottage, M.D., Achillion's Chief Medical Officer, will participate in a panel discussion on Monday, February 12 at the 2007 BIO CEO and Investor Conference in New York City. The panel is a Therapeutic Workshop scheduled for 3:30PM entitled, "Novel H...
PDF
Nov 8, 2006
NEW HAVEN, Conn., Nov 08, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) today announced that it closed the sale of an additional 675,000 shares of its common stock in connection with the exercise of the over-allotment option granted to the underwriters of its recent initial public offering of ...
PDF
Oct 26, 2006
New Haven, Conn., Oct 26, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) today announced the pricing of its initial public offering of 4,500,000 shares of its common stock at $11.50 per share, before underwriting discounts and commissions. All of the common stock is being offered by Achillion. ...
PDF
Apr 3, 2006
New Haven, Conn, April 3, 2006 — Achillion Pharmaceuticals, Inc., announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of shares of its common stock. All shares of the common stock to be sold ...
PDF
Nov 4, 2005
New Haven, CT, November 4, 2005 — Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, Chief Executive Officer of Achillion, will be presenting a corporat...
PDF
Sep 22, 2005
New Haven, CT, September 22, 2005 — Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, Chief Executive Officer of Achillion will be presenting a corpora...
PDF
Aug 15, 2005
Foster City, CA and New Haven, CT, August 15, 2005 —Gilead Sciences (Nasdaq: GILD) and Achillion Pharmaceuticals today announced that the companies have begun dosing patients in a Phase I study of GS 9132, also known as ACH-806. Gilead and Achillion are investigating GS 9132 for the treatment o...
PDF
May 2, 2005
New Haven, CT, May 2, 2005 — Achillion Pharmaceuticals Inc., today announced that the Company has received a Phase 1 Small Business Innovation Research Grant (SBIR) from the National Institute of Allergy and Infectious Disease (NIAID) branch of the National Institutes of Health (NIH). The grant cov...
PDF
Mar 23, 2005
New Haven, CT, March 23, 2005 — Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced two management promotions. Milind S. Deshpande, Ph.D. was named Chief Scientific Officer an...
PDF
FirstPrevious
...
25
NextLast